Clinical Trials for Coronary Artery Disease
This article provides information about ongoing clinical trials for coronary artery disease, a condition where the blood vessels supplying the heart become narrowed or blocked. There are currently 23 active trials investigating various treatments including medications to prevent blood clots, reduce inflammation, lower cholesterol, and improve outcomes after heart procedures. These trials are taking place across multiple countries in Europe, offering opportunities for patients at different stages of the disease. (Also known as: CAD, Coronary Heart Disease, Chronic Coronary Syndrome)
Clinical trial locations
- Austria
- Belgium
- Study on Colchicine for Patients with Coronary Artery Disease After Percutaneous Coronary Intervention
- Study on Reduced Antiplatelet Therapy with Acetylsalicylic Acid and Clopidogrel for Patients with Coronary Artery Disease After Stent Implantation
- Study on Inclisiran and Statin Therapy for Patients with Non-obstructive Coronary Artery Disease to Assess Atherosclerotic Plaque Progression
- Denmark
- Espagne
- Finland
- Study on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions
- Study Comparing Drug-Coated Balloon and Drug-Eluting Stents in Patients with Coronary Artery Disease at High Risk of Bleeding Using Acetylsalicylic Acid and Drug Combination
- Study on the Effects of Oxycodone and Paracetamol in Patients with Heart Valve or Coronary Artery Disease After Cardiac Surgery
- Study on Ticagrelor and Acetylsalicylic Acid for Patients with Acute Coronary Syndrome Undergoing Coronary Artery Bypass Grafting
- France
- Study on Reduced Antiplatelet Therapy with Acetylsalicylic Acid and Clopidogrel for Patients with Coronary Artery Disease After Stent Implantation
- Study Comparing Drug-Coated Balloon and Drug-Eluting Stents in Patients with Coronary Artery Disease at High Risk of Bleeding Using Acetylsalicylic Acid and Drug Combination
- Study on Inclisiran and Statin Therapy for Patients with Non-obstructive Coronary Artery Disease to Assess Atherosclerotic Plaque Progression
- Study on the Effect of Influenza Vaccine on Inflammation in Patients with Stable Coronary Artery Disease Using B/Phuket/3073/2013-like Virus and Drug Combination
- Germany
- Study on O15-Water for Diagnosing Coronary Artery Disease in Patients Using PET Imaging During Stress and Rest Conditions
- Study on Reduced Antiplatelet Therapy with Acetylsalicylic Acid and Clopidogrel for Patients with Coronary Artery Disease After Stent Implantation
- Study on the Effects of Ticagrelor and Acetylsalicylic Acid in Patients with Coronary Artery Disease Undergoing CABG Surgery
- Study on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions
- Greece
- Hungary
- Iceland
- See more trials
Study on Colchicine for Patients with Coronary Artery Disease After Percutaneous Coronary Intervention
This trial is investigating whether colchicine, a medication traditionally used to treat gout, can help reduce the risk of serious heart-related events in patients who have undergone percutaneous coronary intervention. The procedure involves opening blocked heart arteries using a small tube or balloon.
Who can participate: Adults aged 45 or older who have coronary artery disease treated with PCI and are on optimal medical therapy. Participants must have at least one additional risk factor such as diabetes, current smoking, high blood pressure, high cholesterol, or a history of vascular disease. Enrollment must occur between 2 hours and 5 days after the PCI procedure.
Who cannot participate: Patients with severe allergic reactions to the study medication, severe liver or kidney disease, those who are pregnant or breastfeeding, those currently in another clinical trial, or those with alcohol or drug abuse history are excluded.
What the trial studies: The trial aims to determine if taking colchicine daily can lower the chances of major cardiovascular events such as heart attacks, strokes, or the need for further heart procedures. The study will follow participants over time to monitor their health and track any heart-related events.
Medications tested: Colchicine 0.5 mg taken orally once daily in tablet form. The medication works by inhibiting proteins that contribute to inflammation, which may help reduce the risk of cardiovascular events.
Study on Coronary Artery Disease: Evaluating Myocardial Blood Flow Using SYN2, Regadenoson, and Adenosine in Patients with Heart Conditions
This research uses a new imaging agent called SYN2 to measure blood flow in the heart. The study compares SYN2 with traditional imaging methods to see if it provides accurate measurements of heart blood flow.
Who can participate: Adults over 18 years of age with suspected coronary artery disease who are willing to follow all study procedures. Participants must either have had a 13N-ammonia PET study within 30 days without significant treatment changes, or be willing to undergo both this test and the SYN2 study.
Who cannot participate: The exclusion criteria for this trial are not fully detailed in the available information, but generally patients who cannot undergo imaging procedures would not be eligible.
What the trial studies: The main goal is to understand how well SYN2 can measure blood flow in the heart compared to traditional methods. This could help improve the diagnosis and treatment of coronary artery disease in the future.
Medications tested: SYN2 solution for injection, along with Rapiscan (regadenoson) and adenosine, which help with the imaging process by affecting blood flow to show any blockages more clearly.
Study on Flecainide and Amiodarone for Treating Atrial Fibrillation in Patients with Coronary Artery Disease and Ejection Fraction Over 35%
This trial examines whether flecainide is more effective than amiodarone in converting irregular heartbeats back to normal rhythm in emergency department settings for patients with both coronary artery disease and atrial fibrillation.
Who can participate: Adults aged 18-25 years with paroxysmal atrial fibrillation confirmed by ECG that started less than 48 hours before emergency department arrival, or 48 hours to 7 days with at least 30 days of blood-thinning medication. Patients must have a history of coronary artery disease without ongoing heart muscle damage and a heart pumping ability above 35%.
Who cannot participate: Patients with a heart pumping ability of 35% or less, those with ongoing lack of blood flow to the heart, those not experiencing paroxysmal atrial fibrillation, or those not in the emergency department are excluded.
What the trial studies: The study aims to determine if flecainide is better than amiodarone in helping patients return to normal heart rhythm while being at least as safe. Monitoring includes checking for side effects and complications for up to 24 hours.
Medications tested: Flecainide and amiodarone, both given through injection. These medications help restore normal heart rhythm by stabilizing the heart’s electrical activity.
Study on O15-Water for Diagnosing Coronary Artery Disease in Patients Using PET Imaging During Stress and Rest Conditions
This trial tests a special type of water containing radioactive oxygen to help doctors visualize blood flow to the heart using PET imaging. The goal is to improve the accuracy of diagnosing coronary artery disease.
Who can participate: Men and women aged 18 or older who have been referred for invasive coronary angiography or had one with no treatment, or had a coronary CT angiogram showing minimal disease. Women of childbearing potential must have a negative pregnancy test and use appropriate birth control.
Who cannot participate: Patients with a history of coronary artery disease, those who have undergone invasive coronary angiogram with fractional flow reserve or similar tests, or those who have had a coronary CT angiogram are excluded.
What the trial studies: The study evaluates how well O15-Water can identify coronary artery disease when the heart is at rest and during stress, comparing results to standard tests that look at the heart’s blood vessels.
Medications tested: 15O-H2O, a radioactive water solution given intravenously. It emits signals that PET scanners detect to create images showing how well blood flows to the heart muscle.
Study on Personalized Anti-Platelet Therapy with Prasugrel, Clopidogrel, and Ticagrelor for Patients with Stable Coronary Artery Disease Undergoing Stenting
This study explores whether using genetic testing to choose anti-platelet medications can improve treatment effectiveness for patients undergoing stent placement to keep their heart blood vessels open.
Who can participate: Adults aged 18 or older with chronic coronary syndrome who have undergone successful elective percutaneous coronary intervention with stent placement. Participants must provide written informed consent.
Who cannot participate: Patients with conditions making study participation unsafe, those unable to follow procedures, pregnant or breastfeeding women, those with severe allergies to study medications, current participation in another trial, history of drug or alcohol abuse, unstable medical conditions requiring immediate treatment, recent heart attack or stroke (within 6 months), or severe liver or kidney disease are excluded.
What the trial studies: The research determines if using a personalized approach based on genetic makeup can improve the effectiveness of anti-platelet treatment. The study measures how well medications prevent platelets from clumping together over six months.
Medications tested: Efient (prasugrel) 10 mg, Plavix (clopidogrel) 75 mg, Brilique (ticagrelor) 90 mg, and Aspirine 100 mg, all taken orally as tablets.
Study on Propofol and Remifentanil for Patients with Heart Disease Undergoing Cardiac Anesthesia with Cardiopulmonary Bypass
This trial evaluates a model that predicts how propofol and remifentanil behave in the body during heart surgery involving a heart-lung machine. The research aims to improve anesthesia care during these procedures.
Who can participate: Adults aged 18-90 years scheduled for elective cardiac surgery with cardiopulmonary bypass. Patients must be able to provide informed consent.
Who cannot participate: People with valvular heart disease, coronary heart disease, or aortic disorders cannot participate.
What the trial studies: The study examines how accurately the Eleveld Pharmacokinetic Model can predict medication levels during surgery. Researchers compare actual blood levels with predicted levels to improve understanding of how these medications work during heart surgeries.
Medications tested: Propofol emulsion for injection or infusion and remifentanil solution for injection or infusion. Both are administered intravenously to maintain anesthesia and pain control during surgery.
Study on Reduced Antiplatelet Therapy with Acetylsalicylic Acid and Clopidogrel for Patients with Coronary Artery Disease After Stent Implantation
This research compares different durations of dual antiplatelet therapy after stent implantation. The study evaluates whether a shorter treatment period is as effective as standard therapy while reducing bleeding risks.
Who can participate: Adults aged 18-94 years with one or more coronary artery narrowings of 50% or more in natural arteries or bypass vessels at least 2.00 mm wide. Patients must understand study details and agree to participate by signing a consent form.
Who cannot participate: Patients with known allergies to stent materials, those unable to take antiplatelet medications, those with bleeding disorders, recent heart attack or stroke (within last month), severe liver or kidney disease, pregnant or breastfeeding women, those in another clinical trial, or those with any condition making participation unsafe are excluded.
What the trial studies: The trial aims to determine if abbreviated antiplatelet therapy is as effective as standard therapy in preventing heart-related issues while reducing bleeding risk. Participants are followed for up to 12 months.
Medications tested: Acetylsalicylic acid (aspirin) at 75 mg or 300 mg daily, clopidogrel, ticagrelor, and prasugrel, all taken orally in tablet form. The Angiolite and Xience stent families are also being compared.
Study on Rivaroxaban for Patients with Atrial Fibrillation and Coronary Artery Disease After Heart Procedure
This study examines whether rivaroxaban can be safely used as the only medication for patients with atrial fibrillation who have undergone percutaneous coronary intervention to open blocked heart blood vessels.
Who can participate: Adults aged 18 or older who have had successful PCI, with a history of or newly diagnosed atrial fibrillation within 72 hours after PCI, requiring long-term oral anticoagulation for at least 1 year, and who were treated with a loading dose of clopidogrel before or during PCI.
Who cannot participate: Patients with a history of coronary artery disease, those who have undergone percutaneous coronary intervention, patients with atrial fibrillation not within the specified age range, or those belonging to a vulnerable population are excluded.
What the trial studies: The research investigates how well rivaroxaban works and how safe it is as a single treatment for patients with atrial fibrillation after PCI. The study monitors for health changes including side effects, complications, heart attacks, strokes, and bleeding events over 6 months.
Medications tested: Rivaroxaban in the form of Xarelto 15 mg and 20 mg film-coated tablets taken orally. The medication helps prevent blood clots, which is important for patients with atrial fibrillation.
Study on the Effects of Semaglutide, Dapagliflozin, and Metformin in Patients with Coronary Artery Disease and Prediabetes
This trial compares the effectiveness of three different medications in slowing down or reversing plaque buildup in heart arteries of patients with coronary artery disease and prediabetes.
Who can participate: Adults aged 18-80 years with coronary artery disease showing at least 20% narrowing in heart blood vessels, confirmed by recent quality heart scan within 3 months. Patients must have prediabetes shown by specific blood tests and have been managing heart health risks stably for at least 4 weeks.
Who cannot participate: Patients with severe allergic reactions to study medications, uncontrolled high blood pressure, severe liver or kidney disease, pregnant or breastfeeding women, those in another trial within 30 days, or those with drug or alcohol abuse history within the past year are excluded.
What the trial studies: The research evaluates which medication is most effective in managing coronary artery disease in patients with prediabetes by monitoring plaque progression using CT scans over 24 months. The study also tracks changes in weight, blood pressure, and cholesterol levels.
Medications tested: Rybelsus (semaglutide) 3 mg, 7 mg, and 14 mg tablets, Forxiga (dapagliflozin) 10 mg tablets, and Formetic (metformin) 500 mg tablets, all taken orally alongside diet and lifestyle modifications.
Study on the Effects of Ticagrelor and Acetylsalicylic Acid in Patients with Coronary Artery Disease Undergoing CABG Surgery
This research examines whether adding ticagrelor to aspirin therapy is more effective than aspirin alone in reducing heart-related events after coronary artery bypass grafting surgery.
Who can participate: Adults aged 18 or older undergoing first-time elective CABG with at least one saphenous vein graft, having chronic coronary disease. Participants must be able to sign informed consent and follow all study procedures with follow-up for at least 5 years.
Who cannot participate: Patients with severe allergic reactions to study medications, active bleeding or high bleeding risk, recent stroke or mini-stroke (within 6 months), severe liver disease, those taking medications that strongly interact with study drugs, history of drug or alcohol abuse within the past year, pregnant or breastfeeding women, those in another trial within 30 days, or those with any condition making participation unsafe are excluded.
What the trial studies: The study aims to determine if ticagrelor combined with aspirin reduces the risk of heart-related events such as heart attacks, strokes, and graft failure at 1 year compared to aspirin alone. Participants are followed for 5 years.
Medications tested: Ticagrelor 90 mg film-coated tablets and acetylsalicylic acid (aspirin) in various forms including 100 mg gastro-resistant tablets and 75 mg tablets, all taken orally. Treatment with ticagrelor plus aspirin lasts 1 month.
Study on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions
This trial tests a new tracer called SYN2 used in PET imaging to help doctors diagnose coronary artery disease by showing how well blood flows to the heart.
Who can participate: Adults over 18 years old scheduled for coronary angiography to assess coronary artery disease. Participants must be capable of undergoing stress imaging protocols involving medication or exercise. Women of reproductive potential must use effective contraception, and males must use contraception for three months after last study medication exposure.
Who cannot participate: People diagnosed with coronary artery disease through previous heart attack or procedures, pregnant or breastfeeding women, people with mental or physical conditions preventing informed consent, those living in institutions, people with allergies to SYN2, individuals unable to undergo heart stress tests, those with heart failure or low heart pumping ability, severe valve disease, planned heart procedures, heart transplant candidates, or those in another study within 30 days are excluded.
What the trial studies: The research evaluates how well SYN2 PET scan performs in diagnosing coronary artery disease compared to standard reference tests. The study measures the sensitivity and specificity of the diagnostic approach.
Medications tested: SYN2, adenosine (6 mg/2 ml solution for injection), and Rapiscan (400 microgram solution for injection), all administered as solutions to aid in imaging heart blood flow.
Summary
These 10 trials represent a diverse range of research approaches for coronary artery disease. Several studies focus on optimizing antiplatelet therapy, which prevents blood clots after heart procedures. Multiple trials are testing medications like colchicine, statins, and newer agents to reduce inflammation and plaque buildup in arteries.
A notable concentration of trials involves patients who have undergone percutaneous coronary intervention or coronary artery bypass surgery, reflecting the importance of post-procedure care. Several studies use advanced imaging techniques like PET scans and CT angiography to better diagnose and monitor the disease.
The Netherlands, Germany, and France appear frequently as trial locations, suggesting strong cardiovascular research programs in these countries. Many trials are investigating personalized approaches, including genetic testing to guide medication selection, which represents an important trend toward individualized treatment.
The research spans from acute emergency situations to stable, chronic disease management. Medication durations range from single doses during imaging to long-term treatments lasting up to 24 months. Safety monitoring for bleeding complications is a common concern across multiple studies, as many treatments involve blood-thinning medications.
